Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma

George Georges; Monica Kraft; Elcio O. Vianna; Richard J. Martin

doi:10.3109/02770909809068216

Human corticotropin-releasing hormone improves overnight FEV₁ in nocturnal asthma

George Georges, Monica Kraft, Elcio O. Vianna, Richard J. Martin

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Corticotropin-releasing hormone (CRH) exhibits anti-inflammatory properties independent of its effect on adrenal function. We investigated the safety and effect of CRH in nocturnal asthma, a disease where inflammation is prominent. Five subjects underwent an overnight infusion of placebo on the first night, CRH at a 2.5 μg/kg/hr on the second night, and three subjects received CRH at 4.0 μg/kg/hr on the third night. A significant improvement occurred in overnight change in forced expiratory volume at 1 sec. % (ΔFEV₁) with CRH (+17.4 ± 9.1%) as opposed to placebo (-25.9 ± 7.1%), p = 0.024. CRH was well tolerated. Further research with CRH may clarify the pathophysiology of nocturnal asthma.

Original language	English (US)
Pages (from-to)	261-265
Number of pages	5
Journal	Journal of Asthma
Volume	35
Issue number	3
DOIs	https://doi.org/10.3109/02770909809068216
State	Published - 1998

Keywords

Corticotropin-releasing hormone
Inflammation
Nocturnal asthma

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Immunology and Allergy
Pulmonary and Respiratory Medicine

Access to Document

10.3109/02770909809068216

Cite this

@article{0b56b23a55da4f009243a597e25f3af9,

title = "Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma",

abstract = "Corticotropin-releasing hormone (CRH) exhibits anti-inflammatory properties independent of its effect on adrenal function. We investigated the safety and effect of CRH in nocturnal asthma, a disease where inflammation is prominent. Five subjects underwent an overnight infusion of placebo on the first night, CRH at a 2.5 μg/kg/hr on the second night, and three subjects received CRH at 4.0 μg/kg/hr on the third night. A significant improvement occurred in overnight change in forced expiratory volume at 1 sec. % (ΔFEV1) with CRH (+17.4 ± 9.1%) as opposed to placebo (-25.9 ± 7.1%), p = 0.024. CRH was well tolerated. Further research with CRH may clarify the pathophysiology of nocturnal asthma.",

keywords = "Corticotropin-releasing hormone, Inflammation, Nocturnal asthma",

author = "George Georges and Monica Kraft and Vianna, {Elcio O.} and Martin, {Richard J.}",

note = "Funding Information: This work was supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI 36577), and the Parker B. Francis Foundation. Human corticotropin-releasing hormone (also known as human corticotropin-releasing factor) was supplied by Neurobiological Technologies Inc., Richmond, CA.",

year = "1998",

doi = "10.3109/02770909809068216",

language = "English (US)",

volume = "35",

pages = "261--265",

journal = "Journal of Asthma",

issn = "0277-0903",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma

AU - Georges, George

AU - Kraft, Monica

AU - Vianna, Elcio O.

AU - Martin, Richard J.

N1 - Funding Information: This work was supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI 36577), and the Parker B. Francis Foundation. Human corticotropin-releasing hormone (also known as human corticotropin-releasing factor) was supplied by Neurobiological Technologies Inc., Richmond, CA.

PY - 1998

Y1 - 1998

N2 - Corticotropin-releasing hormone (CRH) exhibits anti-inflammatory properties independent of its effect on adrenal function. We investigated the safety and effect of CRH in nocturnal asthma, a disease where inflammation is prominent. Five subjects underwent an overnight infusion of placebo on the first night, CRH at a 2.5 μg/kg/hr on the second night, and three subjects received CRH at 4.0 μg/kg/hr on the third night. A significant improvement occurred in overnight change in forced expiratory volume at 1 sec. % (ΔFEV1) with CRH (+17.4 ± 9.1%) as opposed to placebo (-25.9 ± 7.1%), p = 0.024. CRH was well tolerated. Further research with CRH may clarify the pathophysiology of nocturnal asthma.

AB - Corticotropin-releasing hormone (CRH) exhibits anti-inflammatory properties independent of its effect on adrenal function. We investigated the safety and effect of CRH in nocturnal asthma, a disease where inflammation is prominent. Five subjects underwent an overnight infusion of placebo on the first night, CRH at a 2.5 μg/kg/hr on the second night, and three subjects received CRH at 4.0 μg/kg/hr on the third night. A significant improvement occurred in overnight change in forced expiratory volume at 1 sec. % (ΔFEV1) with CRH (+17.4 ± 9.1%) as opposed to placebo (-25.9 ± 7.1%), p = 0.024. CRH was well tolerated. Further research with CRH may clarify the pathophysiology of nocturnal asthma.

KW - Corticotropin-releasing hormone

KW - Inflammation

KW - Nocturnal asthma

UR - http://www.scopus.com/inward/record.url?scp=0031824192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031824192&partnerID=8YFLogxK

U2 - 10.3109/02770909809068216

DO - 10.3109/02770909809068216

M3 - Article

C2 - 9661678

AN - SCOPUS:0031824192

VL - 35

SP - 261

EP - 265

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

IS - 3

ER -